Hong Kong
· Delayed Price · Currency is HKD TYK Medicines Statistics
Total Valuation
TYK Medicines has a market cap or net worth of HKD 11.76 billion. The enterprise value is 11.46 billion.
| Market Cap | 11.76B |
| Enterprise Value | 11.46B |
Important Dates
The next estimated earnings date is Friday, May 30, 2025.
| Earnings Date | May 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TYK Medicines has 370.84 million shares outstanding. The number of shares has increased by 16.91% in one year.
| Current Share Class | 366.23M |
| Shares Outstanding | 370.84M |
| Shares Change (YoY) | +16.91% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.22% |
| Owned by Institutions (%) | 18.72% |
| Float | 214.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 103,239.73 |
| PB Ratio | 23.38 |
| P/TBV Ratio | 27.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -27.82 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -28.19 |
Financial Position
The company has a current ratio of 1.97, with a Debt / Equity ratio of 0.37.
| Current Ratio | 1.97 |
| Quick Ratio | 1.60 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.46 |
| Interest Coverage | -27.34 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -28.86% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -54.86% |
| Revenue Per Employee | 744 |
| Profits Per Employee | -2.69M |
| Employee Count | 153 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 29.83 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 55.46 |
| Average Volume (20 Days) | 2,675,775 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TYK Medicines had revenue of HKD 113,866 and -411.79 million in losses. Loss per share was -1.22.
| Revenue | 113,866 |
| Gross Profit | 14,898 |
| Operating Income | -365.82M |
| Pretax Income | -412.82M |
| Net Income | -411.79M |
| EBITDA | -349.93M |
| EBIT | -365.82M |
| Loss Per Share | -1.22 |
Balance Sheet
The company has 490.01 million in cash and 188.20 million in debt, giving a net cash position of 301.82 million or 0.81 per share.
| Cash & Cash Equivalents | 490.01M |
| Total Debt | 188.20M |
| Net Cash | 301.82M |
| Net Cash Per Share | 0.81 |
| Equity (Book Value) | 502.89M |
| Book Value Per Share | 1.35 |
| Working Capital | 297.86M |
Cash Flow
In the last 12 months, operating cash flow was -328.03 million and capital expenditures -78.35 million, giving a free cash flow of -406.38 million.
| Operating Cash Flow | -328.03M |
| Capital Expenditures | -78.35M |
| Free Cash Flow | -406.38M |
| FCF Per Share | -1.10 |
Margins
| Gross Margin | 13.08% |
| Operating Margin | -321,276.00% |
| Pretax Margin | -362,550.92% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TYK Medicines does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.91% |
| Shareholder Yield | -16.91% |
| Earnings Yield | -3.50% |
| FCF Yield | -3.46% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TYK Medicines has an Altman Z-Score of 11.93.
| Altman Z-Score | 11.93 |
| Piotroski F-Score | n/a |